IQVIA (NYSE:IQV) Rating Increased to Buy at Wall Street Zen

IQVIA (NYSE:IQV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other brokerages have also recently issued reports on IQV. Truist Financial restated a “buy” rating and issued a $265.00 target price (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Citigroup raised their price objective on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Finally, BMO Capital Markets initiated coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.19.

IQVIA Trading Down 0.8%

NYSE:IQV opened at $220.75 on Friday. IQVIA has a 1 year low of $134.65 and a 1 year high of $234.29. The stock has a market cap of $37.59 billion, a P/E ratio of 30.28, a P/E/G ratio of 2.50 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a 50-day simple moving average of $219.06 and a 200-day simple moving average of $192.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. lifted its stake in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA in the third quarter valued at about $30,000. Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA during the third quarter worth about $36,000. Finally, Asset Dedication LLC raised its holdings in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.